The severity and number of people affected by cancer is a worldwide problem with millions of people affected annually. The search for treatment and cures of cancer continues to be a global effort. As part of this global effort, many natural products have been tested against cancer cell lines, most from plants located in tropical regions. However, this study reports that extracts of Atriplex confertifolia, a native North American plant, has significant bioactivity against human breast cancer cell lines MCF-7, 435, and 231, and HeLa cells (cervical cancer cells). The bioactivity of A. confertifolia extracts of these cells lines was compared to an FDA-approved cancer drug and an industry-standard leukocyte control cell line. Active portions of the extracts were found primarily in the polar fractions of the plant. A dose-response curve of the extracts clearly showed significant cell death similar to the FDA-approved drug. The plant extracts did not inhibit the viability of the leukocyte cell line. Cancer cell death was followed as a function of time and concentration. Cell death appears to be a result of apoptosis.
College and Department
Life Sciences; Plant and Wildlife Sciences
BYU ScholarsArchive Citation
Capua, Christopher James, "Comparative Cytotoxicity of an FDA-approved Cancer Drug to Extracts of Atriplex confertifolia on Human Breast and Cervical Cancer Cells" (2008). All Theses and Dissertations. 1703.
cancer, treatment, dose response, extracts